

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

ELI LILLY AND COMPANY

By

Queen Thomas

Date

Jan. 14, 2005

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Briner et al.

Serial No. : 10/031,312

Filed : May 6, 2002

Title : BENZOFURYLPIPERAZINES AND
BENZOFURYLHOMOPIPERAZINES
SEROTONIN AGONISTS

Docket No. : X-12592

Group Art Unit:
1624

Examiner:
Emily B. Bernhardt

*Fee Purpose
only*

TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Identification of Person Making This Disclaimer

I, R. Craig Tucker, am employed by Eli Lilly and Company, and I am an attorney of record in the above-identified patent application. In that capacity, I am authorized to sign this disclaimer on behalf of Eli Lilly and Company.

Identity of Assignee

I hereby verify that the assignee owning all of the interest in this application is:

Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285

Recordal of Assignment in PTO

The assignment was recorded on January 15, 2002, Reel 12777, Frame 0841.

10031312

05/10

01/27/2005 CTRAILL 00000004 05/10

130.00 DA

01 FC:1814

Extent of Interest

The extent of Eli Lilly and Company's interest is in the whole of this invention.

Disclaimer

I hereby disclaim the terminal part of any patent granted on this application, which would extend beyond the expiration date of:

United States Patent No. 6,638,936 and hereby agree that any patent granted on this application shall be enforceable only for and during such period that the legal title to the patent shall be the same as the legal title to United States Patent No. 6,638,936.


I do not disclaim any terminal part of any patent granted on this application prior to the expiration date of the full statutory term of United States Patent No. 6,638,936 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its full statutory term other than as presently shortened by any terminal disclaimer.

Fee Payment

Please charge \$110.00, the fee set forth in 37 C.F.R. 1.20(d), and charge any additional fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840 in the name of Eli Lilly and Company. Two copies of this disclaimer are enclosed.

ELI LILLY AND COMPANY

By:



R. Craig Tucker

Registration No. 45,165

Phone: 317-433-9829